Characteristics of all CLL patients using IGHV3-21 gene
. | Total . | France . | Greece . | Italy . | Spain . |
---|---|---|---|---|---|
No. IGHV3-21 cases | 16 | 4 | 7 | 4 | 1 |
Frequency, % | 2.9 | 2.7 | 3.7 | 4.1 | 0.9 |
Mean age, y | 70.7 | 63.5 | 67 | 79.5 | 90* |
Sex, no. F/no. M | 8/8 | 2/2 | 4/3 | 1/3 | 1/0 |
No. mutated/no. unmutated | 7/9 | 2/2 | 2/5 | 2/2 | 1/0 |
IGHV homology, no. | |||||
At least 98% | 9 | 2 | 5 | 2 | 0 |
98%-96% | 3 | 0 | 1 | 1 | 1 |
Less than 96% | 4 | 2 | 1 | 1 | 0 |
LC, no. κ/no. λ | 7/9 | 2/2 | 4/3 | 1/3 | 0/1 |
IGV LC homology, no. | |||||
At least 98% | 14 | 3 | 7 | 3 | 1 |
98%-96% | 2 | 1 | 0 | 1 | 0 |
Less than 96% | 0 | 0 | 0 | 0 | 0 |
CD38, % | |||||
Neg | 5 | 0 | 4 | 1 | 0 |
Pos | 10 | 3 | 3 | 3 | 1 |
Stage at diagnosis | |||||
A | 8 | 1 | 5 | 2 | 0 |
B | 5 | 3 | 1 | 1 | 0 |
C | 3 | 0 | 1 | 1 | 1 |
Clinical course | |||||
Stable | 5 | 0 | 4 | 1 | 0 |
Progressive | 11 | 4 | 3 | 3 | 1 |
Need for treatment | 11 | 4 | 3 | 3 | 1 |
CLL-related death | 4 | 2 | 0 | 1 | 1 |
. | Total . | France . | Greece . | Italy . | Spain . |
---|---|---|---|---|---|
No. IGHV3-21 cases | 16 | 4 | 7 | 4 | 1 |
Frequency, % | 2.9 | 2.7 | 3.7 | 4.1 | 0.9 |
Mean age, y | 70.7 | 63.5 | 67 | 79.5 | 90* |
Sex, no. F/no. M | 8/8 | 2/2 | 4/3 | 1/3 | 1/0 |
No. mutated/no. unmutated | 7/9 | 2/2 | 2/5 | 2/2 | 1/0 |
IGHV homology, no. | |||||
At least 98% | 9 | 2 | 5 | 2 | 0 |
98%-96% | 3 | 0 | 1 | 1 | 1 |
Less than 96% | 4 | 2 | 1 | 1 | 0 |
LC, no. κ/no. λ | 7/9 | 2/2 | 4/3 | 1/3 | 0/1 |
IGV LC homology, no. | |||||
At least 98% | 14 | 3 | 7 | 3 | 1 |
98%-96% | 2 | 1 | 0 | 1 | 0 |
Less than 96% | 0 | 0 | 0 | 0 | 0 |
CD38, % | |||||
Neg | 5 | 0 | 4 | 1 | 0 |
Pos | 10 | 3 | 3 | 3 | 1 |
Stage at diagnosis | |||||
A | 8 | 1 | 5 | 2 | 0 |
B | 5 | 3 | 1 | 1 | 0 |
C | 3 | 0 | 1 | 1 | 1 |
Clinical course | |||||
Stable | 5 | 0 | 4 | 1 | 0 |
Progressive | 11 | 4 | 3 | 3 | 1 |
Need for treatment | 11 | 4 | 3 | 3 | 1 |
CLL-related death | 4 | 2 | 0 | 1 | 1 |
Actual age of the single patient of the Spanish series.